Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 3
2006 2
2007 4
2008 5
2009 4
2010 2
2011 5
2012 2
2013 3
2014 2
2015 7
2016 4
2017 3
2018 7
2019 16
2020 4
2021 1
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 19861557

71 results

Results by year

Filters applied: . Clear all
Page 1
Clonal MET Amplification as a Determinant of Tyrosine Kinase Inhibitor Resistance in Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.
Lai GGY, Lim TH, Lim J, Liew PJR, Kwang XL, Nahar R, Aung ZW, Takano A, Lee YY, Lau DPX, Tan GS, Tan SH, Tan WL, Ang MK, Toh CK, Tan BS, Devanand A, Too CW, Gogna A, Ong BH, Koh TPT, Kanesvaran R, Ng QS, Jain A, Rajasekaran T, Yuan J, Lim TKH, Lim AST, Hillmer AM, Lim WT, Iyer NG, Tam WL, Zhai W, Tan EH, Tan DSW. Lai GGY, et al. J Clin Oncol. 2019 Apr 10;37(11):876-884. doi: 10.1200/JCO.18.00177. Epub 2019 Jan 24. J Clin Oncol. 2019. PMID: 30676858
Role of tyrosine kinase inhibitors in lung cancer.
Ansari J, Palmer DH, Rea DW, Hussain SA. Ansari J, et al. Anticancer Agents Med Chem. 2009 Jun;9(5):569-75. doi: 10.2174/187152009788451879. Anticancer Agents Med Chem. 2009. PMID: 19519298
Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer.
Bonomi PD, Gandara D, Hirsch FR, Kerr KM, Obasaju C, Paz-Ares L, Bellomo C, Bradley JD, Bunn PA Jr, Culligan M, Jett JR, Kim ES, Langer CJ, Natale RB, Novello S, Pérol M, Ramalingam SS, Reck M, Reynolds CH, Smit EF, Socinski MA, Spigel DR, Vansteenkiste JF, Wakelee H, Thatcher N. Bonomi PD, et al. Ann Oncol. 2018 Aug 1;29(8):1701-1709. doi: 10.1093/annonc/mdy196. Ann Oncol. 2018. PMID: 29905778 Free PMC article. Review.
From Diagnostic-Therapeutic Pathways to Real-World Data: A Multicenter Prospective Study on Upfront Treatment for EGFR-Positive Non-Small Cell Lung Cancer (MOST Study).
Pasello G, Vicario G, Zustovich F, Oniga F, Gori S, Rosetti F, Bonetti A, Favaretto A, Toso S, Redelotti R, Santo A, Bernardi D, Giovanis P, Oliani C, Calvetti L, Gatti C, Palazzolo G, Baretta Z, Bortolami A, Bonanno L, Basso M, Menis J, Corte DD, Frega S, Guarneri V, Conte P; Veneto Oncology Network. Pasello G, et al. Oncologist. 2019 Jun;24(6):e318-e326. doi: 10.1634/theoncologist.2018-0712. Epub 2019 Mar 7. Oncologist. 2019. PMID: 30846513 Free PMC article.
Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.
Brugger W, Triller N, Blasinska-Morawiec M, Curescu S, Sakalauskas R, Manikhas GM, Mazieres J, Whittom R, Ward C, Mayne K, Trunzer K, Cappuzzo F. Brugger W, et al. J Clin Oncol. 2011 Nov 1;29(31):4113-20. doi: 10.1200/JCO.2010.31.8162. Epub 2011 Oct 3. J Clin Oncol. 2011. PMID: 21969500 Clinical Trial.
71 results